For the clinical phase, Bayer has acquired the sole global license for an MTA-cooperative PRMT5 inhibitor that targets MTAP-deleted tumors selectively.
articipants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks.
Eliminating amyloid from the brain may prevent symptoms in those who are destined to acquire early-onset Alzheimer’s disease, according to a clinical experiment. This suggests the need for additional research.
In addition to being the first to examine the safety and effectiveness of an automated insulin delivery (AID) system in conjunction with an Abbott FreeStyle Libre® 2 family sensor
The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.
Trial continues as planned to 52 weeks to further characterize the risk-benefit profile.
The trial achieved its primary endpoint, as previously revealed at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.
Islatravir, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), inhibits HIV-1 replication through a variety of mechanisms
At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
